WO2023211893A1 - Dual t1/t2 mri contrast agents for photothermal therapy - Google Patents
Dual t1/t2 mri contrast agents for photothermal therapy Download PDFInfo
- Publication number
- WO2023211893A1 WO2023211893A1 PCT/US2023/019749 US2023019749W WO2023211893A1 WO 2023211893 A1 WO2023211893 A1 WO 2023211893A1 US 2023019749 W US2023019749 W US 2023019749W WO 2023211893 A1 WO2023211893 A1 WO 2023211893A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticles
- magnetic resonance
- resonance imaging
- composite
- enhancement agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
Definitions
- NPs nanoparticles
- metallic NPs carbon-based NPs
- organic/inorganic nanohybrid NPs organic/inorganic nanohybrid NPs
- Nanoparticles with optical properties in the near-infrared (NIR) have opened a new avenue to phototherm ally treat solid tumors.
- NIR illumination at the nanoparticle plasmon resonance induces collective oscillations of the nanoparticle conduction band electrons, causing an increase in local temperature that can initiate various cell death pathways.
- This invention was funded in part by the Robert A. Welch Foundation under Welch Grant No. C-1220.
- one or more embodiments disclosed herein relate to a photothermal magnetic resonance imaging (MRI) enhancement agent.
- the photothermal magnetic resonance imaging enhancement agent includes a plurality of composite nanoparticles, each composite nanoparticle includes a dielectric inner layer with a porous substrate having pores, a plurality of magnetically responsive nanoparticles disposed on the porous substrate, and a metallic outer layer around the inner layer and the magnetically responsive nanoparticles.
- the core when the inner layer is a core, the core includes a dielectric material.
- the inner layer is disposed around a core, such that the composite nanoparticles discussed herein include the core, the inner layer, one or more magnetically responsive nanoparticles, and an outer layer.
- the core when the inner layer is disposed around a core, the core includes a metallic material.
- the metallic material in the core may be the same or different than the metallic material in the outer layer.
- an average outer diameter of the inner layer is between about 80 nm and about 110 nm.
- the inner layer includes a dielectric core.
- the inner layer includes a dielectric layer disposed around a metallic core.
- the magnetically responsive nanoparticles have an average diameter between about 2 nm and about 3 nm.
- the magnetically responsive nanoparticles include gadolinium oxide.
- the composite nanoparticle has a relaxivity rate n of at least 3.6 times greater than a reference gadopentetate dimeglumine Ti MRI contrast agent. [0014] In one or more embodiments, the composite nanoparticle has a relaxivity rate xi comparable to a reference superparamagnetic iron oxide T2 MRI contrast agent.
- the composite nanoparticle is a type 1 contrast agent and a type 2 contrast agent.
- a surface area of the porous substrate is between about 900 m 2 /g to about 1000 m 2 /g.
- an average pore diameter of the pores is between about 1.5 nm and about 4 nm.
- the porous substrate includes a dielectric material selected from the group consisting of silicon dioxide, titanium dioxide, PMMA, polystyrene, dendrimers, and combinations thereof.
- the porous substrate includes mesoporous silica.
- the metal includes gold.
- the metallic material includes a metal shell with an average thickness of about 10 nm to about 30 nm.
- the composite nanoparticle further includes a coating surrounding the metallic material, wherein the coating includes molecules that allow one or more of improved nanoparticle stability, facilitating bypassing of an immune system, targeting cells, and increased circulation time.
- the composite nanoparticle has a surface plasmon resonance between about 800 nm to about 1100 nm.
- the composite nanoparticle induces a temperature increase of about 20 to about 55°C upon irradiation with a NIR laser at a laser power of between about 1W to about 5 W.
- one or more embodiments disclosed herein relate to a method of making a photothermal magnetic resonance imaging enhancement agent.
- the method includes synthesizing a dielectric substrate, baking the dielectric substrate to generate pores within the dielectric substrate, synthesizing magnetically responsive nanoparticles, loading the magnetically responsive nanoparticles into the pores of the dielectric substrate so as to form a dielectric inner layer comprising the dielectric substrate and the magnetically responsive nanoparticles, attaching a plurality of linker molecules to the dielectric core, attaching a metal nanoparticle to each of at least a portion of the linker molecules, reducing additional metal onto the metal nanoparticles so as to form an outer layer disposed on the dielectric inner layer, and selecting a condition of the reducing such that the outer layer has a controllable thickness forming a composite nanoparticle.
- one or more embodiments describe a system for visualizing and inducing hyperthermia in a cell or tissue comprising the steps of synthesizing composite nanoparticles, delivering the composite nanoparticles to the cell or tissue, visualizing the composite nanoparticles to ensure site specific delivery, and exposing the composite nanoparticles to infrared radiation under conditions where the composite nanoparticles emit heat upon exposure to the infrared radiation.
- FIG. 1 A shows a of cross-sectional schematic of a composite nanoparticle in accordance with one or more embodiments
- FIG. IB shows a of cross-sectional schematic of a composite nanoparticle in accordance with one or more embodiments
- FIG. 3A shows an exemplary transmission electron microscope (TEM) image of a plurality of non-conducting dielectric inner layers formed during the synthesis of a plurality of composite nanoparticles in accordance with one or more embodiments where the scale bar indicates 50 nm;
- TEM transmission electron microscope
- FIG. 3B shows an exemplary transmission electron microscope (TEM) image of a plurality of magnetically responsive nanoparticles formed during the synthesis of a plurality of composite nanoparticles, where the scale bar indicates 20 nm;
- TEM transmission electron microscope
- FIG. 3C shows an exemplary histogram plot of the diameter distribution of a plurality of Gd 2 O 3 -mesoporous silica nanoparticles in accordance with one or more embodiments
- FIG. 3D shows an exemplary transmission electron microscope (TEM) image of a composite nanoparticle in accordance with one or more embodiments, where the scale bar indicates 50 nm;
- TEM transmission electron microscope
- FIG. 4A shows exemplary extinction spectra of a plurality of composite nanoparticles as a function of outer layer thickness in accordance with one or more embodiments
- FIG. 4B shows an exemplary plot the outer layer thickness distribution determined by high-resolution transmission electron microscopy of a plurality of composite nanoparticles in accordance with one or more embodiments
- FIG. 4C shows an exemplary plot the outer layer thickness distribution determined by high-resolution transmission electron microscopy of a plurality of composite nanoparticles in accordance with one or more embodiments
- FIG. 4D shows an exemplary plot the outer layer thickness distribution determined by high-resolution transmission electron microscopy of a plurality of composite nanoparticles in accordance with one or more embodiments
- FIG. 5 A shows exemplary plots of longitudinal magnetization recovery (Ti) vs. recovery time at various Gd 3+ concentrations of composite nanoparticles in water in accordance with one or more embodiments;
- FIG. 5B shows exemplary plots of the decay of transverse magnetization recovery (T2) vs. echo time at various Gd 3+ concentrations of composite nanoparticles in water in accordance with one or more embodiments;
- FIG. 5C shows an exemplary image of the Ti-weighted (Ti w ) enhancement at various Gd 3+ concentrations of composite nanoparticles in water in accordance with one or more embodiments;
- FIG. 5D shows an exemplary image of the T2-weighted fhw) enhancement at various Gd 3+ concentrations of composite nanoparticles in water in accordance with one or more embodiments
- FIG. 5E shows an exemplary plot of the Ri and R2 relaxivity as a function of Gd(III) ion concentration in composite nanoparticles in water in accordance with one or more embodiments
- FIG. 5F shows an exemplary plot of the ri and r2 relaxivity rates and their ratio n/n of a plurality of composite nanoparticles with different outer layer thickness, magnetically responsive nanoparticles, dielectric inner layers comprising a porous substrate with magnetically responsive nanoparticles in the pores and attached metal nanoparticles, and comparative MRI contrast agents in water in accordance with one or more embodiments;
- FIG. 5G shows an exemplary plot of the enhancement factor of a plurality of particles of a plurality of composite nanoparticles with different outer layer thickness, magnetically responsive nanoparticles, dielectric inner layers comprising a porous substrate with magnetically responsive nanoparticles in the pores and attached metal nanoparticles, and comparative MRI contrast agents relative to a standard Ti MRI contrast agent in water in accordance with one or more embodiments;
- FIG. 5H shows an exemplary plot of ri relaxivity rate values versus gold outer layer thickness in water in accordance with one or more embodiments
- FIG. 6A shows exemplary plots of longitudinal magnetization recovery (Ti) vs. recovery time at different concentrations of composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments;
- FIG. 6B shows exemplary plots of decay of transverse magnetization recovery (T2) vs. echo time at different concentrations of composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments
- FIG. 6C shows an exemplary plot of the Ri and R2 relaxivity as a function of Gd(III) ion concentration in composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments;
- FIG. 6D shows an exemplary Ti map values of composite nanoparticles at different concentrations in 0.48% agarose phantoms in accordance with one or more embodiments
- FIG. 6E shows an exemplary T2 map values of composite nanoparticles at different concentrations in 0.48% agarose phantoms in accordance with one or more embodiments
- FIG. 7A shows exemplary plots of longitudinal magnetization recovery (Ti) vs. recovery time of different concentrations of composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments;
- FIG. 7B shows exemplary plots of the decay of transverse magnetization recovery (T2) vs. echo time of different concentrations of composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments;
- FIG. 7C show exemplary T2 W MR images of different concentrations of composite nanoparticles in 0.48% agarose phantoms at different echo times according to one or more embodiments
- FIG. 7F shows an exemplary plot of MRI signal intensities relative to water MR images in FIG. 5E according to one or more embodiments
- FIG. 9D shows an exemplary plot of the temperature change during photothermal treatment at different concentrations of composite nanoparticles in 0.48% agarose phantoms in accordance with one or more embodiments.
- One or more embodiments of the present disclosure may combine the composite nanoparticles with an antibody and/or peptide targeting and/or therapeutic actuation.
- the antibody may be present in a coating.
- An exemplary antibody is a folate receptor adapted for targeting cancer cells.
- antibody targeting may be used such that the composite nanoparticles may bind to the surface receptors of specific cell types.
- the composite nanoparticles may allow for the tracking the location of the particles in vivo.
- photothermal magnetic resonance imaging may be used to follow the path of the particles or verify the quantity of particles at specific locations. Once verified, ablation of the targeted cells may be carried out by photothermal ablation.
- the composite nanoparticles described herein may be used for one or more of a variety of imaging application and light induced drug release of therapeutic molecules.
- one or more embodiments of the present disclosure relate to methods, devices, materials, and/or systems including composite nanoparticles.
- the composite nanoparticles may be used in hyperthermia in a cell or tissue.
- the composite nanoparticles may enable imaging, targeted drug delivery, and photothermal therapy to be conducted. Further, the composite nanoparticles may be used to perform other processes without departing from the invention.
- each composite nanoparticle or a portion of the composite nanoparticles may be one or more of photothermal-active and magnetically responsive, e.g., generate photothermal response and/or MRI contrast when illuminated and/or imaged using an appropriate technique.
- the photothermal magnetic resonance contrast enhancement agent may be a dual type 1 (Ti) and type (T2) contrast agent.
- the composite nanoparticles may have a photothermal response upon NIR laser illumination.
- the photothermal response of the composite nanoparticle may be used for photothermal therapy.
- the composite nanoparticle induces a temperature increase of about 20 to about 55°C upon irradiation with a NIR laser at a laser power of between about 1 W to about 5 W.
- the composite nanoparticles discussed herein include an inner layer, one or more magnetically responsive nanoparticles, and an outer layer around the inner layer and the magnetically responsive nanoparticles.
- the outer layer is a shell around a core.
- the inner layer may be the core.
- the inner layer maybe disposed around the core.
- the outer layer includes a metallic material.
- the inner layer is a nonconducting dielectric material.
- the dielectric material is selected from the group consisting of silicon dioxide, titanium dioxide, PMMA, polystyrene, dendrimers, and combinations thereof.
- the inner layer may be a different dielectric material than those listed above without departing from the present disclosure.
- the inner layer is mesoporous silica (SiCh).
- the inner layer is a porous substrate having pores.
- the pores may have an average pore size of about 1.5 nm to about 4 nm in one or more embodiments.
- the average outer diameter of the inner layer in one or more embodiments may have a lower limit of one of 1.5 nm, 1.6 nm, 1.7 nm, 1.8 nm, 1.9 nm, 2.0 nm, 2.1 nm, 2.2 nm, 2.3 nm, 2.4 nm, and 2.5 nm and an upper limit of one of 2.6 nm,
- the surface area of the porous substrate is between about 900 m 2 /g to about 1000 m 2 /g.
- the average surface area of the porous substrate in one or more embodiments may have a lower limit of one of 900 m 2 /g, 905 m 2 /g, 910 m 2 /g, 905 m 2 /g, 920 m 2 /g, 925 m 2 /g, 930 m 2 /g, 935 m 2 /g, and 940 m 2 /g and an upper limit of one of 945 m 2 /g, 950 m 2 /g, 955 m 2 /g, 960 m 2 /g, 965 m 2 /g, 970 m 2 /g, 975 m 2 /g, 980 m 2 /g, 985 m 2 /g, 990 m 2 /g, 995 m 2 /g,
- the pores house at least one magnetically responsive nanoparticle.
- the magnetically responsive nanoparticles may be paramagnetic or ferromagnetic.
- the magnetically responsive nanoparticle is a dual Ti/ T2 MRI contrast agent.
- the magnetically responsive nanoparticle is a transition metal and/or a rare earth metal.
- the transition metal and/or a lanthanide are selected from gadolinium (III), iron (II), iron (III) and/or manganese (II).
- the magnetically responsive nanoparticle may include any number, type, and/or combination of metal ions without departing from the disclosure.
- the magnetically responsive nanoparticle may be gadolinium oxide (Gd 2 O 3 ).
- the Gd(III) may include any Gd(III) organic framework.
- the magnetically responsive nanoparticle has an average hydrodynamic diameter of about 2 nm to about 4 nm.
- the average hydrodynamic diameter of the magnetically responsive nanoparticle in one or more embodiments may have a lower limit of one of 2.0 nm, 2.1 nm, 2.2 nm, 2.3 nm, 2.4 nm, 2.5 nm, 2.6 nm, 2.7 nm, 2.8 nm, 2.9 nm, and 3.0 nm and an upper limit of one of 3.1 nm, 3.2 nm, 3.3 nm, 3.4 nm, 3.5 nm, 3.6 nm, 3.7 nm, 3.8 nm, 3.9 nm and 4.0 nm.
- magnetically responsive nanoparticles are disposed on the inner layer.
- the magnetically responsive nanoparticles may be disposed in the pores of the inner layer.
- the magnetically responsive nanoparticles in the pores may be disposed on the surfaces of the pores of the dielectric core.
- magnetically responsive nanoparticles in the pores may also be on the inner layer.
- the magnetically responding nanoparticles may be disposed in pores in an outer portion of the inner layer.
- the outer portion of the inner layer is the exterior surface of the inner layer.
- the outer portion of the inner layer is a surface region of the inner layer.
- the magnetically response nanoparticles may be additionally disposed in pores in an interior portion of the inner layer.
- the interior portion of the inner layer is the bulk of the inner layer. In one or more embodiments, the outer and interior portions combine to form the whole of the inner layer. In one or more embodiments, 50% of the magnetically responsive nanoparticles may be distributed in an outer portion of the inner layer and 50% may be uniformly distributed in the bulk of the inner layer.
- the magnetically responsive nanoparticles may be doped with a linker molecule. The linker molecule may facilitate the attachment of the magnetically responsive nanoparticles to the inner layer. Linker molecules may include but are not limited to amino silanes, carboxy silanes, or hydroxy silanes.
- the outer layer may be disposed around the inner layer and the magnetically responsive nanoparticles.
- the outer layer may encapsulate the dielectric core and the magnetically responsive nanoparticles.
- the outer layer may be a metallic material.
- the metallic material may be, for example, coinage metals, noble metals, transition metals, and synthetic metals.
- the outer layer may be a different metallic material than those listed above without departing from the present disclosure.
- the outer layer may be gold.
- the outer layer may have other materials disposed on an exterior side of the outer layer.
- polymeric, ceramic, targeting molecules, fluorescing material, other MRI-contrast agents or other materials may be disposed on an exterior surface of the outer layer.
- the outer layer may include a fluorescing material.
- the fluorescing material may be attached or chemically linked to the outer layer.
- the fluorescing material may be, for example, a fluorescing dye.
- the exterior of the outer layer may be functionalized with molecules including polyethylene glycol (PEG), DNA/aptamers, proteins, polypeptides, antibodies, or other polymeric molecules.
- the thickness of the outer layer may be from about 10 nm to about 50 nm.
- the thickness of the outer layer in one or more embodiments may have a lower limit of one of 10 nm, 11 nm, 12 nm, 13 nm, 14 nm, 15 nm, 16 nm, 17 nm, 18 nm, 19 nm, 20.0 nm, 21 nm, 22 nm, 23 nm, 24 nm, 25 nm, 26 nm, 27 nm, 28 nm, 29 nm, 30 nm, 31 nm, 32 nm, 33 nm, 34 nm, and 35 nm, and an upper limit of one of 36 nm, 37 nm, 38 nm, 39 nm, 40 nm, 41 nm, 42 nm, 43 nm, 44 nm, 45 nm, 46 nm, 47 nm, 48 n
- the thickness of the outer layer may allow for tailoring photothermal magnetic resonance imaging enhancement agent to have a plasmon resonance that is tuned to the near- IR window of the electromagnetic spectrum (i.e., from about 700 nm to 2500 nm). Nearinfrared light can penetrate biological tissues more efficiently than visible light because tissue scatters and absorbs less light at the longer NIR wavelengths,
- the particles according to the present disclosure may have a plasmon resonance that peaks in a region between about 800 nm and 1350 nm. These particular wavelengths may be particularly preferred for in vivo imaging because they can improve signal-to-noise ratios by reducing background noise caused by tissue.
- the outer layer may contain a monolayer of a polymer.
- the polymer in one or more embodiments may be a polyethylene glycol-based polymer.
- the polyethylene glycol-based polymer monolayer may improve composite nanoparticle stability, facilitate the bypassing of the immune system, and increase circulation time in in vivo studies.
- the molecular weight of the polyethylene glycol based-polymer may be between about 1000 Da to about 5000 Da.
- the molecular weight of the polyethylene glycol based-polymer in one or more embodiments may have a lower limit of one of 1000 Da, 1500 Da, 2000 Da, and 2500 Da and an upper limit of one of 3000 Da, 3500 Da, 4000 Da, 4500 Da, and 5000 Da.
- the polyethylene glycol based- polymer is methoxy-polyethylene glycol thiol.
- FIG. 1A illustrates a schematic representation of a cross-section of a composite nanoparticle (100).
- the particle may include a dielectric inner layer (102), magnetically responsive nanoparticles (104) attached to the dielectric inner layer (102), and a metallic outer layer (106).
- the dielectric inner layer includes a porous substrate. The porous substrate extends throughout an outer region (108).
- FIG. 2 illustrates a schematic representation of a cross-section of a composite nanoparticle (200).
- the particle may include a metal core (202), a dielectric inner layer (204), magnetically responsive nanoparticles (206) attached to the dielectric inner layer (204), and a metallic outer layer (208).
- the dielectric inner layer includes a porous substrate. The porous substrate extends throughout an outer region (210).
- MRI magnetic resonance imaging
- Ti agents are positive contrast agents that make an image brighter on MRI phantoms.
- T2 agents are negative contrast agents that cause a darker image on MRI phantoms.
- Commercial Ti contrast agents tend to need to be in direct contact with water to produce its effect while T2 agents tend not to need to be in direct contact with water.
- Thermal magnetic resonance imaging (MRI) mapping can correlate thermal damage with the extent of thermal necrosis and enable real-time temperature evaluation during PTT.
- the magnetically responsive nanoparticle is a dual type 1/type 2 MRI contrast agent.
- Composite nanoparticles of the present disclosure may be dual T1/T2 MRI contrast agents and have a strong plasmon resonance in the NIR region where tissue is highly transparent (known as the first NIR therapeutic window).
- the dual T 1 and T2 MRI properties enhance MRI visualization in Ti weighted (Ti w ) MRI and T2 weighted (Tiw) MRI.
- incorporating magnetically responsive nanoparticles within the dielectric porous substrate and encapsulating with a metal shell improves the n and r2 relaxivity values of magnetically responsive nanoparticles by at least 1 and 4 times respectively.
- This increase may be due to the decrease in the tumbling rate of the composite nanoparticle (TR) and the increase in the water exchange rate (xm) caused by the confinement space the channels and the pores within the structure were creating.
- Forming a continuous metal shell and increasing the metal shell thickness may decrease the relaxivity rates similarly as predicted by Solomon-Bloembergen-Morgan (SBM) theory.
- the present composite nanoparticles may have a relaxivity rate, r 2 , comparable to a reference superparamagnetic iron oxide T2 MRI contrast agent.
- a composite nanoparticle concentration of about 1.0x10 9 composite nanoparti cles/mL to about 9.0x10 9 composite nanoparti cles/mL causes a temperature of between 15°C to 60°C in agarose phantoms.
- photothermal magnetic resonance imaging enhancement agent comprises a plurality of composite nanoparticles.
- photothermal magnetic resonance imaging contrast enhancement agent is produced using a four step process including coating gold or other core material particles with APTES-doped dielectric, loading water and Gadolinium or other contrast material into the APTES-doped dielectric inner layer, etching the dielectric inner layer and seeding the dielectric inner layer with gold, and coating the dielectric inner layer with an outer layer of gold.
- Cetyltrimethylammonium chloride was purchased from Sisco Research Laboratories Pvt. Ltd. Ammonium hydroxide solution (28 % NH3 in water), Tetraethyl orthosilicate (TEOS, >99.9%), acetone (>99.5%), gadolinium(III) chloride hexahydrate (GdCl 3 6H 2 O, >99%), diethylene glycol (DEG, 99%), (3 -aminopropyl)-tri ethoxy silane (APTES, 99%), sodium chloride (NaCl, >99%), and Tetrakis(hydroxymethyl) phosphonium chloride (THPC, 80% in water) were purchased from Sigma- Aldrich.
- Multi-element internal standard (2-wt % HN03, 10 mg/L Ho) were purchased from Atomic Spectroscopy.
- Gadolinium 1CP/DCP standard solution (10,006 pg/mL in 2-wt % HNO 3 ) and hydrochloric acid (HC1, >30%) were purchased from Fluka Analytical.
- Sodium hydroxide solution NaOH, 1 N
- potassium carbonate anhydrous K 2 CO 3 , ⁇ 99%
- nitric acid HNO 3 , 70%
- Aqua regia HNO 3 /HCI (v/v), 1:3) was used to clean laboratory glassware and stir bars, followed by thorough rinsing with Dl-Water. Milli-Q water (18.2 M ⁇ .cm at 25 °C, Millipore) was used during all of the reactions and the last step of glassware washing.
- FIG. 3A is an exemplary TEM image of a plurality of silica nanoparticles synthesized.
- Adsorption is defined as the adhesion of atoms or molecules of gas to a surface. The amount of gas adsorbed depends on the exposed surface area. During BET analysis, the amount of gas adsorbed on a surface is measured.
- ultrasmall Gd 2 O 3 nanoparticle (NP) synthesis was performed under an argon environment attached to the condensation system to better control the oxidation process.
- 5.8 g of gadolinium (III) chloride hexahydrate was dissolved in 100 mL of di ethylene glycol in a 250 mL round beaker. The solution was heated to at 60 °C, the temperature was maintained, and the solution was stirred overnight. 22.5 mL of 1 N NaOH was added quickly and vigorously stirred at 750 rpm while the temperature was increased to 140 °C at 5 °C/min ramping rate (RR).
- RR °C/min ramping rate
- the average hydrodynamic diameter of the synthesized Gd 2 O 3 nanoparticles was 3.0 ⁇ 0.3 nm, as determined by dynamic light scattering measurements and TEM images.
- FIG. 3B is an exemplary TEM image of a plurality of synthesized Gd 2 O 3 nanoparticles.
- 3C is an exemplary histogram plot showing the average size distribution of aminated Gd 2 O 3 -MS NPs.
- the total number of Gd 2 O 3 -MS NPs measured to generate the plot were 2,930.
- the average diameter of the Gd 2 O 3 -MS NPs was determined to be 95 ⁇ nm by a Gaussian distribution fit (300).
- a plating solution was prepared by adding 50 mg of potassium carbonate to 200 mL of Milli-Q water followed by 3 mL of 1% wt chloroauric gold solution. The plating solution was shaken for approximately 1 minute and left in the dark overnight. The gold-seed Gd 2 O 3 -MSs solution from was refreshed by 15 min of sonication. The gold shell was grown around the Gd 2 O 3 -MSs cores via seed-mediated electroless plating. The electroless deposition was achieved by reducing gold from a 1.8 mM potassium carbonate solution and 0.4 pM chloroauric acid by formaldehyde.
- the gold shell thickness was tuned to match the extinction spectrum for a maximum at the 810 nm laser wavelength.
- the reaction was scaled up by running multiple reactions. Every five cuvettes (3 mL each) were combined in a 50 mL centrifuge tube and centrifuged at 350xg for 30 minutes while avoiding composite nanoparticle aggregation. The pellets were collected and redispersed in water, mildly sonicated, recentrifuged for two more times.
- the photothermal magnetic resonance imaging contrast enhancement agent is monodispersed in size and the outer dimension of each composite nanoparticle is less than 150 nm.
- FIG. 3D is an exemplary TEM image of a composite nanoparticle synthesized with a scale bar of 50 nm.
- the plasmon resonance of the photothermal magnetic resonance imaging contrast enhancement agent may be tuned from 600 nm to about 900 nm by varying the metal shell thickness when measured.
- the extinction spectra of three aqueous suspension of PEGylated composite nanoparticles with varying metal shell thicknesses are shown in FIG. 4A.
- the extinction spectra reveal a blue shift in the plasmon resonance with an increase in gold shell thickness, as predicted by Mie theory.
- FIG. 4A shows the extinction spectra of composite nanoparticles with an average metal shell thickness of 22 nm (402), 27.5 nm (404), and 31 nm (406).
- the average metal shell thickness was determined by high resolution transmission electron microscopy.
- the plot in FIG. 4B was obtained by imaging and measuring the diameter of 304 composite nanoparticles.
- FIG. 4B corresponds to a shell thickness of 22 nm and spectrum 402 in FIG. 4A.
- the plot in FIG. 4C was obtained by imaging and measuring the diameter of 339 composite nanoparticles.
- FIG. 4C corresponds to a shell thickness of 27.5 nm and spectrum 404 in FIG. 4A.
- the plot in FIG. 4C was obtained by imaging and measuring the diameter of 297 composite nanoparticles.
- FIG. 4C corresponds to a shell thickness of 31 nm and spectrum 406 in FIG. 4A.
- the composite nanoparticle distributions were fit using a Gaussian function to obtain the shell thicknesses.
- the Gaussian fit (408) determined the average shell thickness to be 22 ⁇ 2.5 nm.
- Tn FIG. 4C the Gaussian fit (410) determined the average shell thickness to be 27.5 ⁇ 0.5 nm.
- the Gaussian fit (412) determined the average shell thickness to be 31 ⁇ 2 nm.
- Gadolinium ion concentration [00127] The MRI contrast was measured as a function of the Gd 3+ concentration. The concentration of Gd 3+ within composite nanoparticle samples was measured using a Perkin Elmer Nexion 300 ICP-MS. Initially, 25 ⁇ L of each composite nanoparticle sample was digested in 200 ⁇ L concentrated aqua regia and left overnight with a loss cover. The resulting solutions were diluted with 2% v/v nitric acid (HNO3) by 400 times. Furthermore, various Gadolinium ICP/DCP standard solution concentrations with 1, 10, 100, and 1,000 pg/L were prepared to generate a calibration curve. Internal standard (Ho 165) was added to all samples, standard solutions, and a blank solution and kept its final concentration the same (15 pg/L) to ensure no changes within the instrument detection sensitivity occurred during the measurements.
- Ho 165 Internal standard
- Equations 1-2 were used to determine the longitudinal (Ti) and transverse (T2) relaxation time constants, respectively:
- FIG. 5F is an exemplary plot of ri relaxivity rate (left bar), n relaxivity rate (middle bar), n/n ratio (right bar) of Magnevist®, Resovist®, Ferumoxide, Gd 2 O 3 nanoparticles, Gd 2 O 3 -MS with Au seed, and composite nanoparticles with three different shell thicknesses (22 nm, 27.5 nm, and 31 nm).
- FIG. 5F and Table 1 show that Gd 2 O 3 nanoparticles, Gd 2 O 3 nanoparticles containing nanoparticles, and composite nanoparticles have a higher ri relaxivity rate compared to a standard Ti MRI contrast agent like Magnevist®.
- Table 1 shows that the r 1 of composite nanoparticles with 22 nm shell is 3.6> ⁇ r 1 relaxivity rate of Magnevist® (Ti MRI contrast agent).
- T2 relaxation time is sensitive to local changes in the magnetic field. The more perturbation within the local magnetic field, each spin will experience different local magnetic fields, causing them to process at various frequencies, increasing decoherence and inhomogeneity in the transverse plane, and eventually a faster decay of the transverse magnetization is detected. This could explain the 4.4 fold of enhancement in the r 2 of composite naoparticles with 22 nm gold shell, for instance, relative to Gd 2 O 3 . The composite nanoparticles with 22 nm and 27.5 nm gold shells were used for further experimentation since both provided sufficient contrast enhancement and a strong NIR plasmon resonance sufficient to perform MRI-guided PTT.
- NMR tubes were prepared with a 40 ⁇ L layer of 1.1x10 9 (C4), 2.1x10 9 (C3), 4.2x10 9 (C2), and 8.4x10 9 (C1) composite nanoparticles/mL with 27.5 nm shell thickness in 0.48% agarose surrounded with 0.8% agarose suspension.
- the NMR tubes were placed in a square shape with an empty tube in the middle to position and center the diffuser optical fiber with an equal distance from all samples and the same laser power density exposure. A control sample containing water and without composite nanoparticle was used.
- FIGs. 6A and 6B show plots of longitudinal recovery and transverse decay, respectively, for water and C 1 -C 4 samples with increasing concentration (corresponding to curves from top to bottom in FIG. 6B, respectively).
- a is an assumed temperature sensitivity (-0.01 ppm/°C)
- TE is the sequence echo time (6 ms).
- the proton resonance frequency ( ⁇ I) is the product of ⁇ the gyromagnetic ratio (42.58 MHz/T for hydrogen) and Bo magnetic field strength (4.7 T).
- FIG. 8A is a coronal T 1w MRI for one of the NMR tubes with the relevant slices set for thermal MRI measurements to monitor the temperature change during laser illumination.
- the superscript images were axial Ti w MR images of slice # 2 and # 4 across the NMR tubes at composite nanoparticle 804 locations and composite nanoparticle free 806 agarose medium, respectively.
- T 1w MR images were acquired (73 sec/image) to monitor and control the laser treatment in real-time. This set of images covered a baseline, 3 min of 808 nm illumination at 4 W, and temperature recovery measurements.
- the Ti w MR images were processed with a MATLAB code to generate a thermal map for any plane of interest.
- FIG. 9A is a thermal map obtained from the last FLASH image acquired before the laser was turned OFF, presenting the maximum temperature change at the composite nanoparticle location. After three minutes of continuous NIR-illumination at 4 W, the highest temperature change (30 °C ⁇ ⁇ T max ⁇ 54 °C) at the composite nanoparticle locations was achieved close to the illumination source.
- FIG. 9B is the temperature change profile in real-time during MR thermometry at three regions of interest 1) composite nanoparticle with 8.4x 10 9 composite nanoparticle/mL (900), 2) approximately 2 mm below the composite nanoparticle band in the same NMR tube (902), and 3) reference (904), reaching a maximum temperature change of 54 °C, 20 °C, and ⁇ 4 °C, respectively.
- a rapid increase in the temperature (18 °C/min) was detected at the composite nanoparticle locations as soon as the laser illumination was ON (FIG. 9B).
- Increasing composite nanoparticle concentrations increased the localized generated heat until a plateau is reached as shown in FIGs. 9C-D.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/859,947 US20250345465A1 (en) | 2022-04-25 | 2023-04-25 | Dual t1/t2 mri contrast agents for photothermal therapy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263334622P | 2022-04-25 | 2022-04-25 | |
| US63/334,622 | 2022-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023211893A1 true WO2023211893A1 (en) | 2023-11-02 |
Family
ID=86424693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/019749 Ceased WO2023211893A1 (en) | 2022-04-25 | 2023-04-25 | Dual t1/t2 mri contrast agents for photothermal therapy |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20250345465A1 (en) |
| WO (1) | WO2023211893A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160038618A1 (en) * | 2014-08-11 | 2016-02-11 | William Marsh Rice University | Plasmonic sub-100 nm nanomatryoshkas that confine contrast agents within layers of metal |
| US20180008730A1 (en) * | 2014-08-11 | 2018-01-11 | William Marsh Rice University | Multifunctional fluorescent and mri-active nanostructure |
-
2023
- 2023-04-25 US US18/859,947 patent/US20250345465A1/en active Pending
- 2023-04-25 WO PCT/US2023/019749 patent/WO2023211893A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160038618A1 (en) * | 2014-08-11 | 2016-02-11 | William Marsh Rice University | Plasmonic sub-100 nm nanomatryoshkas that confine contrast agents within layers of metal |
| US20180008730A1 (en) * | 2014-08-11 | 2018-01-11 | William Marsh Rice University | Multifunctional fluorescent and mri-active nanostructure |
Non-Patent Citations (6)
| Title |
|---|
| HENDERSON LUKE ET AL: "Routes to Potentially Safer T 1 Magnetic Resonance Imaging Contrast in a Compact Plasmonic Nanoparticle with Enhanced Fluorescence", ACS NANO, vol. 12, no. 8, 8 August 2018 (2018-08-08), US, pages 8214 - 8223, XP093066847, ISSN: 1936-0851, DOI: 10.1021/acsnano.8b03368 * |
| HENDERSON LUKE: "Multifunctional Core-Shell Nanomatryoshkas for Enhanced Imaging Enhanced Imaging", 12 August 2021 (2021-08-12), XP093066904, Retrieved from the Internet <URL:https://scholarship.rice.edu/handle/1911/111205> [retrieved on 20230724] * |
| KADRIA-VILI YARA ET AL: "Gd2O3-mesoporous silica/gold nanoshells: A potential dual T1/T2 contrast agent for MRI-guided localized near-IR photothermal therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 11 July 2022 (2022-07-11), XP093066516, ISSN: 0027-8424 * |
| LI ET AL: "Gadolinium3+-doped mesoporous silica nanoparticles as a potential magnetic resonance tracer for monitoring the migration of stem cells in vivo", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 January 2013 (2013-01-01), pages 119, XP093067405, DOI: 10.2147/IJN.S38213 * |
| MARANGONI VALERIA S. ET AL: "Enhancing T 1 magnetic resonance imaging contrast with internalized gadolinium(III) in a multilayer nanoparticle", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 27, 19 June 2017 (2017-06-19), pages 6960 - 6965, XP093066850, ISSN: 0027-8424, DOI: 10.1073/pnas.1701944114 * |
| WANG HUI ET AL: "High sensitivity of gold nanoparticles co-doped with Gd2O3 mesoporous silica nanocomposite to nasopharyngeal carcinoma cells", SCIENTIFIC REPORTS, vol. 6, no. 1, 3 October 2016 (2016-10-03), XP093066672, Retrieved from the Internet <URL:https://www.nature.com/articles/srep34367.pdf> DOI: 10.1038/srep34367 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250345465A1 (en) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabale et al. | Recent developments in the synthesis, properties, and biomedical applications of core/shell superparamagnetic iron oxide nanoparticles with gold | |
| Wang et al. | Folate-conjugated Fe 3 O 4@ SiO 2@ gold nanorods@ mesoporous SiO 2 hybrid nanomaterial: a theranostic agent for magnetic resonance imaging and photothermal therapy | |
| Li et al. | Hyaluronic acid-modified Fe3O4@ Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors | |
| Xu et al. | Paramagnetic nanoparticle T 1 and T 2 MRI contrast agents | |
| Schladt et al. | Multifunctional superparamagnetic MnO@ SiO 2 core/shell nanoparticles and their application for optical and magnetic resonance imaging | |
| Chen et al. | pH-responsive iron manganese silicate nanoparticles as T 1-T 2* dual-modal imaging probes for tumor diagnosis | |
| Amsaveni et al. | Engineered multifunctional nanoparticles for DLA cancer cells targeting, sorting, MR imaging and drug delivery | |
| Clarke | Development of hierarchical magnetic nanocomposite materials for biomedical applications | |
| Zou et al. | Biodegradable manganese engineered nanocapsules for tumor-sensitive near-infrared persistent luminescence/magnetic resonance imaging and simultaneous chemotherapy | |
| Maximenko et al. | Fe 3 O 4@ SiO 2@ Au nanoparticles for MRI-guided chemo/NIR photothermal therapy of cancer cells | |
| Saha et al. | Fe doped CdTeS magnetic quantum dots for bioimaging | |
| Poorhossein et al. | Designing a multifunctional nanoplatform based on PEGylated cobalt ferrite magnetic nanoparticles containing capecitabine for cancer theranostics | |
| Fudimura et al. | Synthesis and characterization of methylene blue-containing silica-coated magnetic nanoparticles for photodynamic therapy | |
| Selvam et al. | Multifunctional ferromagnetic nanodiamond for dual-mode fluorescence imaging and magnetic drug targeting | |
| Xu et al. | Near infrared window active magnetic core spiky gold nanostars for dual mode imaging and photothermal therapy | |
| Mohammad et al. | Luteinizing hormone-releasing hormone targeted superparamagnetic gold nanoshells for a combination therapy of hyperthermia and controlled drug delivery | |
| US20250345465A1 (en) | Dual t1/t2 mri contrast agents for photothermal therapy | |
| Ma et al. | Folic acid-targeted magnetic Tb-doped CeF 3 fluorescent nanoparticles as bimodal probes for cellular fluorescence and magnetic resonance imaging | |
| Cassim et al. | Development of novel magnetic nanoparticles for hyperthermia cancer therapy | |
| Javed et al. | Gold–Iron Oxide Nanohybrids: Characterization and Biomedical Applications | |
| Bony et al. | Non-specific Zn2+ ion sensing using ultrasmall gadolinium oxide nanoparticle as a magnetic resonance imaging contrast agent | |
| Weigl | Paramagnetic resonance study of the photothermal properties of iron oxide: towards optimized photothermal therapy | |
| Ormelli | Magnetoplasmonic nanoparticles for photothermal therapy | |
| Mehrabifard et al. | Ultrasmall Superparamagnetic Iron Oxide Nanoparticles as Emerging Contrast Agents for Enhanced T2-Weighted Magnetic Resonance Imaging | |
| Bui et al. | Multimodal Contrast Agent Enabling pH Sensing Based on Organically Functionalized Gold Nanoshells with Mn-Zn Ferrite Cores. Nanomaterials 2022, 12, 428 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23725032 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18859947 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 23725032 Country of ref document: EP Kind code of ref document: A1 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18859947 Country of ref document: US |
